Oncology News | pharmaphorum

News

FDA fast-tracks Leap’s gastric cancer immunotherapy

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regula

News

New data reinforce Keytruda's dominance in first-line lung c...

Five-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off a growing number of contenders to the first-line non-small cell lung cancer (NSC

News

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

The FDA has given a 27 March 2021 review date for Bristol-Myers Squibb’s multiple myeloma cell therapy ide-cel, just in time to meet a contingent value right (CVR) due to Celgene shareholde

News

Amgen offers hope in KRAS-mutated cancer with sotorasib read...

Last year Amgen intrigued scientists and investors alike after announcing data showing it had produced the first drug that seemed to work against KRAS mutations, which are found in lung and

News

EU regulators back uses for AZ's Lynparza in prostate and ov...

AstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s busy pipeline is producing successes in other areas.

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Immunomedics wows ESMO with breast cancer data reveal

Immunomedics has revealed the trial data that convinced Gilead to stage a

FDA fast-tracks Leap’s gastric cancer immunotherapy

New data reinforce Keytruda's dominance in first-line lung c...

FDA’s review date for BMS’ ide-cel sneaks under the CVR wire

Amgen offers hope in KRAS-mutated cancer with sotorasib read...

EU regulators back uses for AZ's Lynparza in prostate and ov...

Immunomedics wows ESMO with breast cancer data reveal

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks